$5.63
+0.07(1.35%)
Mkt Cap $390M
$4.15
$10.77
52-Week Range
At A Glance
1
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer.
2
Revenue is primarily driven by Product (75.6%) and Copiktra License And Related Assets (24.4%).
3
Most recently: . Item 7.01 Regulation FD Disclosure On February 4, 2026, the Company issued a press release outlining key 2026 strategic priorities, a copy of which is furnish (2026-02-04).
$390M
Market Cap
$26M
Revenue
-$174M
Net Income
Employees78
Fundamentals
How The Business Makes Money
Revenue by Segment
Product75.6%($62M)
Copiktra License And Related Assets24.4%($20M)
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001526119
ISINUS92337C2035
CUSIP92337C104
Phone781 292 4200
Address117 Kendrick Street, Needham, MA, 02494, US
SEC EDGAR